MCID: CRH005
MIFTS: 52

Crohn's Colitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Crohn's Colitis

MalaCards integrated aliases for Crohn's Colitis:

Name: Crohn's Colitis 12 15 17
Crohn Disease 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060192
ICD9CM 34 555.1
MeSH 43 D003424
SNOMED-CT 67 50440006 7620006
ICD10 32 K50.1
UMLS 71 C0010346 C0156147

Summaries for Crohn's Colitis

Disease Ontology : 12 An inflammatory bowel disease characterized by inflammation located in colon only, has symptom diarrhea, has symptom rectal bleeding, has symptom skin lesions and has symptom formation of ulcers, fistulas and abscesses around the anus.

MalaCards based summary : Crohn's Colitis, also known as crohn disease, is related to inflammatory bowel disease 1 and intestinal tuberculosis, and has symptoms including diarrhea, skin lesions and rectal bleeding. An important gene associated with Crohn's Colitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Clofazimine and Rifabutin have been mentioned in the context of this disorder. Affiliated tissues include colon only, colon and bone, and related phenotype is neoplasm.

Related Diseases for Crohn's Colitis

Diseases related to Crohn's Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 748)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 1 34.0 TNF NOD2 CCR6
2 intestinal tuberculosis 30.9 TNF NOD2 IFNG
3 hidradenitis suppurativa 30.9 TNF NOD2 IFNG
4 hidradenitis 30.9 TNF NOD2 IFNG
5 pustulosis of palm and sole 30.8 TNF CXCL8 CCR6
6 cytomegalovirus infection 30.6 TNF IL1B CXCL8
7 pouchitis 30.6 NOD2 CXCL8
8 blau syndrome 30.5 TNF NOD2 IL1B
9 retinal vascular disease 30.4 TNF IL1B CXCL8
10 ulcerative colitis 30.4 TNF NOD2 IL2 IL1B IFNG CXCL8
11 diarrhea 30.4 TNF IL2 IL1B IFNG CXCL8
12 appendicitis 30.4 TNF IL2 IL1B IFNG CXCL8
13 iritis 30.3 TNF NOD2 CCR6
14 familial mediterranean fever 30.3 TNF NOD2 IL1B
15 sclerosing cholangitis 30.3 TNF NOD2 IL2 CXCL8
16 cholangitis 30.3 TNF NOD2 IL2 CXCL8
17 peritonitis 30.2 TNF NOS2 IL1B IFNG CXCL8
18 pharyngitis 30.2 TNF IL1B CXCL8
19 adult-onset still's disease 30.2 TNF IL1B CXCL8
20 endocarditis 30.2 TNF IFNG CXCL8
21 measles 30.2 TNF IL2 IL1B IFNG
22 histoplasmosis 30.2 TNF IFNG CCR6
23 chronic granulomatous disease 30.2 TNF IL1B IFNG CXCL8
24 exanthem 30.2 TNF IL2 CXCL8 CCR6
25 esophagitis 30.2 TNF IL1B CXCL8
26 inflammatory bowel disease 18 30.2 NOD2 IL2 CCR6
27 keratitis, hereditary 30.2 TNF IL1B CXCL8 CCR6
28 stomatitis 30.2 TNF IL2 IL1B IFNG CXCL8
29 osteomyelitis 30.2 TNF NOD2 IL1B IFNG CXCL8
30 optic neuritis 30.1 TNF IL1B CXCL8
31 pyoderma 30.1 TNF NOD2 CXCL8 CCR6
32 pyoderma gangrenosum 30.1 TNF NOD2 CXCL8 CCR6
33 neurofibromatosis, type ii 30.1 TNF CXCL8 CCR6
34 gastrointestinal tuberculosis 30.1 TNF NOD2 IFNG
35 abdominal tuberculosis 30.1 TNF NOD2 IFNG
36 microscopic colitis 30.1 TNF IL2 IFNG
37 monocytic leukemia 30.1 TNF IL1B IFNG CXCL8
38 central nervous system vasculitis 30.1 TNF IFNG CCR6
39 alcoholic liver cirrhosis 30.1 TNF IL1B CXCL8
40 blepharitis 30.1 TNF CXCL8 CCR6
41 ileus 30.1 TNF IL1B IFNG
42 myelitis 30.1 TNF CXCL8 CCR6
43 rectal disease 30.1 TNF IL2 CXCL8 CCR6
44 dysentery 30.1 TNF IL1B CXCL8 CCR6
45 spondyloarthropathy 1 30.0 TNF NOD2 CCR6
46 spinal cord injury 30.0 TNF NOS2 CXCL8
47 bronchiolitis obliterans 30.0 TNF IFNG CXCL8
48 bronchiolitis 30.0 TNF IFNG CXCL8
49 dengue hemorrhagic fever 30.0 TNF IFNG CXCL8
50 paracoccidioidomycosis 30.0 TNF IL2 IFNG

Graphical network of the top 20 diseases related to Crohn's Colitis:



Diseases related to Crohn's Colitis

Symptoms & Phenotypes for Crohn's Colitis

Symptoms:

12
  • diarrhea
  • skin lesions
  • rectal bleeding
  • formation of ulcers

UMLS symptoms related to Crohn's Colitis:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Crohn's Colitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 CDH1 IFNG IL1B IL2 NOS2 TMEFF2

Drugs & Therapeutics for Crohn's Colitis

Drugs for Crohn's Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
2
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
3
Prucalopride Approved Phase 4 179474-81-8
4
Metronidazole Approved Phase 4 443-48-1 4173
5
Azithromycin Approved Phase 4 83905-01-5 55185 447043
6
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
7
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
8
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
9
Ustekinumab Approved, Investigational Phase 4 815610-63-0
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
13
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
14
Caffeine Approved Phase 4 58-08-2 2519
15
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
16
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
17
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
18
Ondansetron Approved Phase 4 99614-02-5 4595
19
Losartan Approved Phase 4 114798-26-4 3961
20
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
21
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
22
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
23
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
24
Vancomycin Approved Phase 4 1404-90-6 441141 14969
25
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
27
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
28
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
29
Racepinephrine Approved Phase 4 329-65-7 838
30
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
31
Certolizumab pegol Approved Phase 4 428863-50-7
32
tannic acid Approved Phase 4 1401-55-4
33
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
34
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
35
Mercaptopurine Approved Phase 4 50-44-2 667490
36
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
37
leucovorin Approved Phase 4 58-05-9 6006 143
38
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
39
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
40 Serotonin Agents Phase 4
41 Serotonin Receptor Agonists Phase 4
42 Anti-Bacterial Agents Phase 4
43 Antiparasitic Agents Phase 4
44 Antiprotozoal Agents Phase 4
45 Antibiotics, Antitubercular Phase 4
46 Soybean oil, phospholipid emulsion Phase 4
47 Parenteral Nutrition Solutions Phase 4
48 Fat Emulsions, Intravenous Phase 4
49 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
50 calcium channel blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 1143)
# Name Status NCT ID Phase Drugs
1 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
2 A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
3 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
4 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
5 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
6 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
7 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
8 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
9 Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy Unknown status NCT01024647 Phase 4
10 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
11 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study Unknown status NCT01817426 Phase 4 Infliximab
12 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
13 Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
14 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
15 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
16 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
17 Vitamin D and Immunomodulation: Effects in Crohn's Disease Completed NCT01369667 Phase 4
18 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
19 Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study) Completed NCT02148718 Phase 4
20 EUS Guided Treatment With Humira for Crohn's Perianal Fistulas Completed NCT00517296 Phase 4 adalimumab
21 Vitamin D and Its Effects on Inflammation and Intestinal Permeability in Crohn's Disease in Remission Completed NCT01792388 Phase 4
22 A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease Completed NCT01183845 Phase 4
23 A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies Completed NCT00280956 Phase 4 natalizumab
24 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
25 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
26 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
27 Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease Completed NCT00546546 Phase 4 early immunosuppressants (azathioprine, methotrexate)
28 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
29 A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease Completed NCT01442025 Phase 4 Infliximab;Infliximab;Infliximab
30 SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Completed NCT02199626 Phase 4
31 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
32 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
33 The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux Completed NCT00554710 Phase 4 infliximab+azathioprine;methylprednisolone or budesonide
34 Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tbl. 500 mg in Children With Crohn´s Disease Completed NCT00225810 Phase 4 Crohn's Disease
35 Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases Completed NCT00462072 Phase 4 Infliximab
36 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
37 Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study Completed NCT02349594 Phase 4 Omegaven 10%;Intralipid 20%
38 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
39 A Cluster Randomized Controlled Trial of a Treatment Algorithm for the Management of Crohn's Disease Completed NCT01030809 Phase 4
40 The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study) Completed NCT01181765 Phase 4
41 A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE) Completed NCT02630966 Phase 4 Vedolizumab;Placebo
42 Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography Completed NCT02946203 Phase 4
43 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
44 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
45 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
46 Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
47 Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease Completed NCT01947010 Phase 4
48 Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab Completed NCT01556672 Phase 4 Adalimumab
49 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
50 Phase 4, Open Lable Non Randomized un Controlled Study. Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation Completed NCT02269358 Phase 4 METHOTREXATE

Search NIH Clinical Center for Crohn's Colitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


aminosalicylic acid
Azathioprine
Cholecalciferol
natalizumab
Opium
OPIUM ALKALOIDS HYDROCHLORIDE
OPIUM, POWDERED
paregoric
Thalidomide

Cochrane evidence based reviews: crohn disease

Genetic Tests for Crohn's Colitis

Anatomical Context for Crohn's Colitis

The Foundational Model of Anatomy Ontology organs/tissues related to Crohn's Colitis:

19
Colon Only

MalaCards organs/tissues related to Crohn's Colitis:

40
Colon, Bone, T Cells, Testes, Skin, Small Intestine, Liver

Publications for Crohn's Colitis

Articles related to Crohn's Colitis:

(show top 50) (show all 4702)
# Title Authors PMID Year
1
Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease. 61
32010877 2020
2
Do Patients With Inflammatory Bowel Disease Have a Higher Postoperative Risk of Venous Thromboembolism or Do They Undergo More High-risk Operations? 61
30169396 2020
3
Enteropathic spondyloarthritis: Results from a large nationwide database analysis. 61
31838160 2020
4
Laparoscopy in Crohn Disease: Learning Curve and Current Practice. 61
30080737 2020
5
Magnetic Resonance in Crohn Disease: Imaging Biomarkers in Assessing Response to Therapy. 61
31753236 2020
6
Primary Cutaneous Follicle Center Lymphoma in a 16-Year-old boy With Crohn Disease Exposed to Infliximab and Methotrexate. 61
31978035 2020
7
Magnetic Resonance in Crohn's Disease: Diagnosis, Disease Burden, and Classification. 61
31753235 2020
8
Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease: The SuPREMe-CD Study - A Randomized Clinical Trial. 61
32039987 2020
9
Orofacial granulomatosis: a questionnaire study among Norwegian dental clinicians. 61
32020549 2020
10
Lymphocyte-predominant Esophagitis: A Distinct and Likely Immune-mediated Disorder Encompassing Lymphocytic and Lichenoid Esophagitis. 61
31651525 2020
11
Intake of dairy protein during pregnancy in IBD and risk of SGA in a Norwegian population-based mother and child cohort. 61
32013916 2020
12
Differentiation of Colonic Inflammatory Bowel Disease: Re-examination of Paediatric Inflammatory Bowel Disease Classes Algorithm With Resected Colon As the Criterion Standard. 61
31978020 2020
13
Parental Psychological Factors and Quality of Life of Children With Inflammatory Bowel Disease. 61
31978019 2020
14
Laparoscopic Total Proctocolectomy for Crohn's Colitis - video vignette. 61
31970846 2020
15
Role of the δ-Opioid Receptor in 2 Murine Models of Colitis. 61
31969211 2020
16
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. 61
31914087 2020
17
Superior Mesenteric Vein Thrombosis in a Pediatric Patient: Case Report and Review of the Literature. 61
31977781 2020
18
Obesity is more common in children newly diagnosed with ulcerative colitis as compared to those with Crohn's disease. 61
31977953 2020
19
Small Bowel Crohn Disease at CT and MR Enterography: Imaging Atlas and Glossary of Terms. 61
31951512 2020
20
What factors are associated with the eventual need for an ileostomy after total abdominal colectomy and ileosigmoid or ileorectal anastomosis for Crohn's colitis in the biologic era? 61
32015288 2020
21
Intestinal ulcers as an initial finding in EBV-associated lymphoproliferative disorder: A case report. 61
32011464 2020
22
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. 61
31112238 2020
23
The microbiome and inflammatory bowel disease. 61
31910984 2020
24
Emerging views of mitophagy in immunity and autoimmune diseases. 61
30951392 2020
25
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients. 61
31912484 2020
26
Dietary Gluten as a Conditioning Factor of the Gut Microbiota in Celiac Disease. 61
31399743 2020
27
Scurvy may occur even in children with no underlying risk factors: a case report. 61
31973768 2020
28
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. 61
31286804 2020
29
Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease. 61
31764438 2019
30
Direct Evidence of an Increasing Mutational Load in Humans. 61
31424543 2019
31
Small-Bowel Crohn Disease Treated With Anti-Tumor Necrosis Factor-α Therapy: MR Enterography Score Changes After 1 Year Predict Long-Term Outcomes. 61
31414894 2019
32
Serum proteome profiles to differentiate Crohn disease from intestinal tuberculosis and primary intestinal lymphoma: A pilot study. 61
31852111 2019
33
Personalized Nutrition: Are We There Yet? 61
31765333 2019
34
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. 61
31862477 2019
35
Crohn Disease-Associated Genital Edema. 61
31851286 2019
36
Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. 61
31821444 2019
37
A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice. 61
31748792 2019
38
Correlation of Dickkopf-1 with Inflammation in Crohn Disease. 61
31729323 2019
39
The triangular nasal notch sign in patients with Crohn disease treated with tumour necrosis factor inhibitors. 61
31145467 2019
40
Imaging Features Associated With Failure of Nonoperative Management of Intraabdominal Abscesses in Crohn Disease. 61
31294779 2019
41
Metastatic Crohn Disease: A Clinicohistological Appraisal From a Tertiary Care Center in India. 61
31693502 2019
42
Usefulness of Strain Elastography, ARFI Imaging, and Point Shear Wave Elastography for the Assessment of Crohn Disease Strictures. 61
30920016 2019
43
Incidence of Paediatric Stricturing Duodenal Crohn Disease: A 19-Year Population-based Cohort Study. 61
31335835 2019
44
Penetrating Crohn Disease Is Not Associated With a Higher Risk of Recurrence After Surgery: A Prospective Nationwide Cohort Conducted by the Getaid Chirurgie Group. 61
31567506 2019
45
Hidradenitis Suppurativa: Rapid Evidence Review. 61
31674740 2019
46
Using a Steroid-sparing Tool in Paediatric Inflammatory Bowel Disease to Evaluate Steroid Use and Dependency. 61
31436708 2019
47
Clinicopathological significance of lymphocytic colitis/collagenous colitis in inflammatory bowel disease. 61
31698005 2019
48
Vaccine-Preventable Diseases in Hospitalized Patients With Inflammatory Bowel Disease: A Nationwide Cohort Analysis. 61
31067308 2019
49
A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease. 61
31219936 2019
50
Depression Predicts Prolonged Length of Hospital Stay in Pediatric Inflammatory Bowel Disease. 61
31261246 2019

Variations for Crohn's Colitis

Expression for Crohn's Colitis

Search GEO for disease gene expression data for Crohn's Colitis.

Pathways for Crohn's Colitis

Pathways related to Crohn's Colitis according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF NOS2 NOD2 IL2 IL1B IFNG
2
Show member pathways
13.35 TNF NOS2 NOD2 IL2 IL1B IFNG
3
Show member pathways
13.08 TNF NOS2 NOD2 IL2 IL1B IFNG
4
Show member pathways
12.84 TNF IL2 IL1B IFNG CXCL8
5 12.83 NOS2 IL2 IFNG CXCL8 CDH1
6
Show member pathways
12.81 TNF IL2 IL1B IFNG CXCL8
7
Show member pathways
12.59 TNF NOD2 IL2 IL1B IFNG
8
Show member pathways
12.57 TNF NOS2 IL2 IL1B IFNG
9
Show member pathways
12.33 TNF IL1B IFNG CXCL8
10
Show member pathways
12.33 TNF IL2 CXCL8 CCR6
11
Show member pathways
12.32 TNF IL2 IL1B IFNG
12
Show member pathways
12.28 TNF NOS2 IL1B IFNG CXCL8
13
Show member pathways
12.26 TNF NOS2 IL1B IFNG
14
Show member pathways
12.25 TNF IL2 IL1B IFNG CXCL8
15
Show member pathways
12.22 TNF NOS2 IL1B CXCL8
16 12.18 TNF NOS2 IFNG CDH1
17 12.18 TNF NOS2 NOD2 IL1B IFNG
18
Show member pathways
12.13 TNF NOS2 IL1B IFNG CXCL8
19 12.06 TNF NOD2 IL1B DEFB103A DEFA5 CXCL8
20
Show member pathways
12.04 TNF IL2 IL1B IFNG
21 11.99 TNF IL2 IL1B CXCL8
22 11.96 TNF NOS2 IL1B CXCL8
23
Show member pathways
11.95 NOS2 IL2 IL1B IFNG
24 11.85 TNF IL1B IFNG CXCL8
25 11.84 TNF NOS2 IL1B IFNG CXCL8
26 11.79 IL2 IFNG CXCL8
27 11.76 NOS2 IL1B IFNG CXCL8
28 11.73 TNF NOS2 IL1B CXCL8
29
Show member pathways
11.72 TNF IL2 IFNG CXCL8
30 11.67 TNF IL2 IL1B IFNG CCR6
31 11.66 TNF IL1B CXCL8
32
Show member pathways
11.64 TNF IL2 IFNG
33 11.61 TNF IL1B CXCL8
34 11.59 NOS2 IFNG CXCL8
35 11.55 TNF IL2 IFNG
36 11.53 TNF IL1B CXCL8
37 11.52 TNF IL2 IL1B IFNG CDH1
38 11.49 TNF IL1B IFNG CXCL8
39 11.48 TNF IL1B IFNG
40 11.46 TNF NOS2 IL1B IFNG
41 11.44 TNF IL2 IL1B IFNG
42 11.4 TNF NOS2 IL2 IL1B IFNG
43 11.38 NOS2 IL1B IFNG
44 11.38 TNF IL1B IFNG
45 11.3 TNF IL1B IFNG
46 11.25 TNF SLIT2 NOS2 IL2 IL1B IFNG
47
Show member pathways
11.23 TNF NOS2 IL2 IL1B IFNG CXCL8
48 11.17 TNF IL2 IL1B IFNG
49 11.02 TNF CXCL8 CDH3
50 11 TNF IL2 IL1B CXCL8 CDH3 CDH1

GO Terms for Crohn's Colitis

Cellular components related to Crohn's Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF TMEFF2 SLIT2 IL2 IL1B IFNG
2 extracellular space GO:0005615 9.32 TNF SLIT2 MIR29A MIR103A2 IL2 IL1B

Biological processes related to Crohn's Colitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 TNF MIR29A IL1B IFNG CDH3
2 immune response GO:0006955 9.99 TNF IL2 IL1B IFNG CXCL8 CCR6
3 negative regulation of gene expression GO:0010629 9.97 TNF NOS2 MIR29A IFNG
4 cytokine-mediated signaling pathway GO:0019221 9.92 TNF NOS2 IL2 IL1B CXCL8
5 positive regulation of protein phosphorylation GO:0001934 9.9 TNF IL2 IL1B IFNG
6 chemotaxis GO:0006935 9.88 SLIT2 DEFB103A CXCL8 CCR6
7 defense response to bacterium GO:0042742 9.88 TNF NOS2 NOD2 DEFB103A DEFA5
8 negative regulation of cell migration GO:0030336 9.85 TMEFF2 SLIT2 MIR29A CDH1
9 defense response to Gram-negative bacterium GO:0050829 9.84 NOS2 DEFB103A DEFA5
10 positive regulation of inflammatory response GO:0050729 9.83 TNF IL2 IL1B
11 positive regulation of JNK cascade GO:0046330 9.83 TNF NOD2 IL1B
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 TNF IL2 IFNG
13 cellular response to organic cyclic compound GO:0071407 9.81 TNF NOD2 IL1B
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 TNF NOD2 IL1B
15 positive regulation of interleukin-6 production GO:0032755 9.8 TNF NOD2 IL1B
16 humoral immune response GO:0006959 9.79 TNF IFNG CCR6
17 positive regulation of phagocytosis GO:0050766 9.75 TNF IL1B IFNG
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.74 TNF IL1B IFNG
19 positive regulation of interferon-gamma production GO:0032729 9.73 TNF IL2 IL1B
20 positive regulation of interleukin-8 production GO:0032757 9.67 TNF NOD2 IL1B
21 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF IL1B
22 negative regulation of amyloid-beta clearance GO:1900222 9.65 TNF IFNG
23 defense response GO:0006952 9.65 TNF NOD2 DEFB103A DEFA5 CXCL8
24 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF IL1B
25 regulation of insulin secretion GO:0050796 9.62 TNF NOS2 IL1B IFNG
26 positive regulation of killing of cells of other organism GO:0051712 9.61 NOS2 IFNG
27 positive regulation of fever generation GO:0031622 9.59 TNF IL1B
28 astrocyte activation GO:0048143 9.58 TNF IL1B IFNG
29 sequestering of triglyceride GO:0030730 9.54 TNF IL1B
30 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.54 TNF IL1B IFNG
31 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 TNF IFNG
32 positive regulation of nitrogen compound metabolic process GO:0051173 9.43 TNF IFNG
33 cellular response to lipopolysaccharide GO:0071222 9.43 TNF NOS2 NOD2 IL1B DEFA5 CXCL8
34 positive regulation of chemokine biosynthetic process GO:0045080 9.33 TNF IL1B IFNG
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 8.8 TNF IL1B IFNG

Molecular functions related to Crohn's Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNF IL2 IL1B IFNG CXCL8

Sources for Crohn's Colitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....